Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weili He

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Therapeutic Innovation & Regulatory Science|September 18, 2018
Benefit-Risk Evaluation and Decision Making: Some Practical InsightsMichael W Colopy, C V Damaraju, Weili He, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Effective Drug Supply for Adaptive Clinical Trials: Recommendations by the DIA Adaptive Design Scientific Working Group Drug Supply SubteamNancy Burnham, Judith Quinlan, Weili He, et al.
Pharmacological Research|August 15, 2025
Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseasesBinhua Zou, Jiehuang Zheng, Weili He, et al.
Journal of Translational Medicine|April 26, 2026
Analysis of the tumor reactivity of autologous TILs and allogeneic γδ T cells via tumor organoid-immune cell cocultureZijun Su, Haishan Li, Dongdong Zhang, et al.
Clinical Breast Cancer|December 15, 2010
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trialAnders Bonde Jensen, Christopher Wynne, Guillermo Ramirez, et al.
Menopause (New York, N.Y.)|February 27, 2014
Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetineJames A Simon, Julie Chandler, Keith Gottesdiener, et al.
Annals of Internal Medicine|November 19, 2019
Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its JobScott R Evans, Robert Bigelow, Christy Chuang-Stein, et al.
BMC Endocrine Disorders|March 14, 2023
A retrospective cohort study of tamoxifen versus surgical treatment for ER-positive gynecomastiaWeili He, Weidong Wei, Qing Zhang, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Addressing Challenges and Opportunities of "Less Well-Understood" Adaptive DesignsWeili He, Paul Gallo, Eva Miller, et al.
Biochemical and Biophysical Research Communications|May 10, 2019
Intraspinal administration of interleukin-7 promotes neuronal apoptosis and limits functional recovery through JAK/STAT5 pathway following spinal cord injuryXiaochen Yuan, Qingbin Wu, Peng Wang, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Therapeutic Innovation & Regulatory Science|September 18, 2018
Benefit-Risk Evaluation and Decision Making: Some Practical InsightsMichael W Colopy, C V Damaraju, Weili He, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Effective Drug Supply for Adaptive Clinical Trials: Recommendations by the DIA Adaptive Design Scientific Working Group Drug Supply SubteamNancy Burnham, Judith Quinlan, Weili He, et al.
Pharmacological Research|August 15, 2025
Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseasesBinhua Zou, Jiehuang Zheng, Weili He, et al.
Journal of Translational Medicine|April 26, 2026
Analysis of the tumor reactivity of autologous TILs and allogeneic γδ T cells via tumor organoid-immune cell cocultureZijun Su, Haishan Li, Dongdong Zhang, et al.
Clinical Breast Cancer|December 15, 2010
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trialAnders Bonde Jensen, Christopher Wynne, Guillermo Ramirez, et al.
Menopause (New York, N.Y.)|February 27, 2014
Diary of hot flashes reported upon occurrence: results of a randomized double-blind study of raloxifene, placebo, and paroxetineJames A Simon, Julie Chandler, Keith Gottesdiener, et al.
Annals of Internal Medicine|November 19, 2019
Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its JobScott R Evans, Robert Bigelow, Christy Chuang-Stein, et al.
BMC Endocrine Disorders|March 14, 2023
A retrospective cohort study of tamoxifen versus surgical treatment for ER-positive gynecomastiaWeili He, Weidong Wei, Qing Zhang, et al.
Therapeutic Innovation & Regulatory Science|September 22, 2018
Addressing Challenges and Opportunities of "Less Well-Understood" Adaptive DesignsWeili He, Paul Gallo, Eva Miller, et al.
Biochemical and Biophysical Research Communications|May 10, 2019
Intraspinal administration of interleukin-7 promotes neuronal apoptosis and limits functional recovery through JAK/STAT5 pathway following spinal cord injuryXiaochen Yuan, Qingbin Wu, Peng Wang, et al.
Pageof 4